Studies Led by Memorial Sloan Kettering Investigators Show Immunotherapy Drugs Improve Outcomes in Hodgkin Lymphoma Patients
Memorial Sloan Kettering Cancer CenterIn recent years, a number of scientific breakthroughs have led to the development of drugs that unleash the power of the immune system to recognize and attack cancer. For Classical Hodgkin lymphoma patients, two phase I studies are already demonstrating dramatic results.